The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Significance: Prostate cancer is the most common malignancy and the third leading cancer-related cause of death among men of the Western world. Treatment options at advanced stages of the disease are scarce, and better therapies are in urgent need. In our study, we show that the clinically relevant lipid kinase phosphatidylinositol-4-phosphate 5-kinase-α (PIP5Kα) plays an important role in cancer cell invasion and survival by regulating the PI3K/AKT/androgen receptor pathways. Elevated levels of PIP5K1α contribute to cancer cell proliferation, survival, and invasion. In this context we introduce a newly developed compound, ISA-2011B, with promising anticancer effects by inhibiting the PIP5K1α-associated AKT pathways. Conclusively, we propose that PIP5K1α may be used as a potential therapeutic target for treatment of advanced prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 13×
“Given that amplification of AKT2 or mutations in PIK3CA, in addition to PTEN mutation, are all responsible for activation of PI3K pathway (15, 38, 39), our data suggest that ISA2011B exerts its on-target effect on PCa cells by targeting pathways related to AKT/AR, rather than a toxic effect.”
BackgroundInfluentialMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Cited by
Understanding phosphoinositides: rare, dynamic, and essential membrane phospholipids
Dickson, E. J., & Hille, B. (2019) · Biochemical Journal · doi:10.1042/bcj20180022 · Cited by 254
Beyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
A P53-Phosphoinositide Signalosome Regulates Nuclear AKT Activation
Chen, M., Choi, S., Wen, T., Chen, C., Thapa, N., Lee, J. H., Cryns, V. L., & Anderson, R. A. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00949-1 · Cited by 117
A Nuclear Phosphoinositide Kinase Complex Regulates P53
Choi, S., Chen, M., Cryns, V. L., & Anderson, R. A. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0297-2 · Cited by 106
Metadata
- Authors
- Semenas, J., Hedblom, A., Miftakhova, R. R., Sarwar, M., Larsson, R., Shcherbina, L., Johansson, M. E., Härkönen, P., Sterner, O., & Persson, J. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-07-28
- Volume
- 111
- Issue
- 35
- Pages
- E3689-98
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2014454127
- Cited by
- 115
- References
- 4
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. https://app.cochat.ai/papers/10.1073/pnas.1405801111
- The paper
- Semenas, J., Hedblom, A., Miftakhova, R. R., Sarwar, M., Larsson, R., Shcherbina, L., Johansson, M. E., Härkönen, P., Sterner, O., & Persson, J. L. (2014). The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1405801111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.